PMID- 28616588
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2372-3556 (Print)
IS  - 2372-3556 (Electronic)
IS  - 2372-3556 (Linking)
VI  - 4
IP  - 3
DP  - 2017
TI  - All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic 
      cancer driven by mutant KRAS.
PG  - e1314239
LID - 10.1080/23723556.2017.1314239 [doi]
LID - e1314239
AB  - KRAS proto-oncogene, GTPase (KRAS) remains refractory to current therapies. We 
      devised an integrative cross-tumor approach to expose common core elements 
      up-regulated in mutant KRAS cancers that could provide new treatment 
      opportunities. This approach identified FOSL1 (Fos-like antigen 1) as a 
      clinically and functionally relevant gene in mutant KRAS-driven lung and 
      pancreatic cancers, and unveiled downstream transcriptional targets amenable to 
      pharmacological inhibition.
FAU - Vallejo, Adrian
AU  - Vallejo A
AD  - Program in Solid Tumors and Biomarkers, Center for Applied Medical Research, 
      Universidad de Navarra, Pamplona, Spain.
AD  - Department of Histology and Pathology, University of Navarra, Pamplona, Spain.
FAU - Valencia, Karmele
AU  - Valencia K
AD  - Program in Solid Tumors and Biomarkers, Center for Applied Medical Research, 
      Universidad de Navarra, Pamplona, Spain.
FAU - Vicent, Silvestre
AU  - Vicent S
AD  - Program in Solid Tumors and Biomarkers, Center for Applied Medical Research, 
      Universidad de Navarra, Pamplona, Spain.
AD  - Department of Histology and Pathology, University of Navarra, Pamplona, Spain.
AD  - IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
LA  - eng
PT  - Journal Article
DEP - 20170405
PL  - United States
TA  - Mol Cell Oncol
JT  - Molecular & cellular oncology
JID - 101642411
PMC - PMC5462508
OTO - NOTNLM
OT  - FOSL1
OT  - KRAS oncogene
OT  - gene signature
OT  - lung cancer
OT  - mouse genetics
OT  - pancreatic cancer
OT  - pharmacological inhibitors
EDAT- 2017/06/16 06:00
MHDA- 2017/06/16 06:01
PMCR- 2018/04/05
CRDT- 2017/06/16 06:00
PHST- 2017/03/28 00:00 [received]
PHST- 2017/03/28 00:00 [revised]
PHST- 2017/03/29 00:00 [accepted]
PHST- 2017/06/16 06:00 [entrez]
PHST- 2017/06/16 06:00 [pubmed]
PHST- 2017/06/16 06:01 [medline]
PHST- 2018/04/05 00:00 [pmc-release]
AID - 1314239 [pii]
AID - 10.1080/23723556.2017.1314239 [doi]
PST - epublish
SO  - Mol Cell Oncol. 2017 Apr 5;4(3):e1314239. doi: 10.1080/23723556.2017.1314239. 
      eCollection 2017.